3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
63
Leukemia, Myeloid, Acute
14
Carcinoma, Non-Small-Cell Lung
14
Lung Neoplasms
11
Lymphoma, Non-Hodgkin
9
Lymphoma, Large B-Cell, Diffuse
9
Recurrence
8
Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Carcinoma, Small Cell
4
Ovarian Neoplasms
3
Leukemia
3
Hodgkin Disease
3
Extensive Stage Small Cell Lung Cancer
3
Small Cell Lung Cancer Extensive Stage
2
SCLC
2
Osteosarcoma
2
Neoplasm Metastasis
2
Lymphoma, B-Cell
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Hematologic Diseases
2
Glioblastoma
2
Ependymoma
2
Advanced Solid Tumors
2
Widespread Small Cell Lung Cancer
1
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Cisplatin
4
Carboplatin
2
viscum album peptide
1
sugemalimab
1
rilotumumab
1
ganitumab
1
endostar protein
1
Zoledronic Acid
1
Valacyclovir
1
Thiostrepton
1
Surgical Procedures, Operative
1
Paclitaxel
1
N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea
1
Etoposide
1
Darbepoetin alfa
1
Cetuximab
1
Catheters, Indwelling
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pleural Effusion, Malignant
×
Etoposide
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts